Comparison of risk factors and outcomes of daptomycin‐susceptible and ‐nonsusceptible vancomycin‐resistant enterococcus faecium infections in liver transplant recipients; A reply to Lewis et al

Clonal distribution of vancomycin‐resistant Enterococcus faecium in Turkey and the new singleton ST733

“…[1][2][3][4][5] Allogenic bone marrow transplant, neutropenia, use of central venous line, and hypoalbuminemia were described as the independent risk factors in the development of the VRE bacteremia in the multi-variant analyses. [6][7][8][9] Although seven different resistance genotypes ( pear to be more deadly and more costly than infections caused by vancomycin-susceptible strains, epidemiological data concerning occurrence and spread of these microorganisms have to be compiled, and VRE isolates have to be epidemiologically investigated.…”

“…Long period of hospitalization in the intensive care, transplant, hematology, or oncology units, receiving hemodialysis, contact with patients diagnosed with VRE, enteral feeding, corticosteroid use, administration of antineoplastic treatment, sucralfate use, and the history of the use of antibiotic (vancomycin, second‐ or third‐generation cephalosporins, metronidazole, clindamycin, imipenem, ticarcillin‐clavulanic acid) were reported as the risk factors 1‐5 . Allogenic bone marrow transplant, neutropenia, use of central venous line, and hypoalbuminemia were described as the independent risk factors in the development of the VRE bacteremia in the multi‐variant analyses 6‐9 …”

Daptomycin perioperative prophylaxis for the prevention of vancomycin‐resistant Enterococcus infection in colonized liver transplant recipients

“…However, in the previously mentioned study by Lewis et al, 11 the DS and DNS groups had similar proportions of daptomycin treatment dosing strategies including 6, 8, or >8 mg/kg of daptomycin, suggesting that the daptomycin dose used does not impact the risk of resistance. Similarly, another study by Jorgenson et al reported that the dose of daptomycin used to treat infection did not seem to be associated with emergence of resistance 18 . In our study, susceptibility testing was not performed for isolates of VRE‐colonized LT candidates, nor for the urine isolate recovered from the single LT recipient with asymptomatic VRE bacteriuria post‐transplant, so the incidence of asymptomatic colonization with DNS VRE could not be assessed.…”